Physician profile
John D Johnson
NPI 1619234945
$1,909.90
in general payments reported to CMS, 2019-2025
28 companies · $220 in 2025
The $220 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $326 · 2020: $202 · 2021: $245 · 2022: $347 · 2023: $321 · 2024: $249 · 2025: $220.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $790.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $790.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $363.30 | 2019-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $166.14 | 2020-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $142.19 | 2019-2025 | Trintellix |
| Bayer Healthcare Pharmaceuticals INC. | $125.69 | 2022-2024 | |
| Lilly USA, LLC | $122.50 | 2020-2025 | Jardiance, Mounjaro |
| Abbott Laboratories | $106.81 | 2021-2023 | Freestyle Libre 3 |
| Astellas Pharma US INC | $103.50 | 2019-2023 | Myrbetriq, Veozah |
| Glaxosmithkline, LLC. | $101.18 | 2019-2021 | |
| Amgen INC. | $95.04 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $68.37 | 2020-2025 | Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.85 | 2020-2022 | |
| Sanofi-Aventis U.S. LLC | $53.05 | 2019-2022 | |
| Abbvie INC. | $47.55 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $47.46 | 2021-2022 | |
| Allergan, INC. | $46.77 | 2019-2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $44.14 | 2023-2024 | Rexulti |
| Merck Sharp & Dohme LLC | $39.36 | 2019-2023 | Verquvo, Steglatro, Belsomra |
| Janssen Pharmaceuticals, INC | $39.24 | 2019 | |
| Mallinckrodt Hospital Products INC. | $18.38 | 2024 | Terlivaz |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.19 | 2025 | Caplyta |
| Amarin Pharma, INC. | $15.45 | 2021 | |
| Genentech USA, INC. | $14.83 | 2019 | |
| Corium, LLC | $14.61 | 2025 | Azstarys |
| Xeris Pharmaceuticals, INC. | $14.60 | 2024 | Gvoke Hypopen |
| Esperion Therapeutics, INC. | $12.58 | 2021 | |
| Nevro Corp. | $12.50 | 2019 | |
| Mylan Specialty L.P. | $11.41 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.21 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.